RMDA Stock Overview
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E., together with its subsidiaries, produces and sells a range of branded generic pharmaceuticals and nutraceuticals in Egypt.
No risks detected for RMDA from our risk checks.
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||ج.م2.85|
|52 Week High||ج.م3.17|
|52 Week Low||ج.م1.80|
|1 Month Change||7.55%|
|3 Month Change||4.40%|
|1 Year Change||16.33%|
|3 Year Change||-11.92%|
|5 Year Change||n/a|
|Change since IPO||-16.49%|
Recent News & Updates
|RMDA||EG Pharmaceuticals||EG Market|
Return vs Industry: RMDA underperformed the EG Pharmaceuticals industry which returned 18.1% over the past year.
Return vs Market: RMDA underperformed the EG Market which returned 22.3% over the past year.
|RMDA Average Weekly Movement||5.3%|
|Pharmaceuticals Industry Average Movement||5.3%|
|Market Average Movement||5.8%|
|10% most volatile stocks in EG Market||9.0%|
|10% least volatile stocks in EG Market||3.6%|
Stable Share Price: RMDA is not significantly more volatile than the rest of EG stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: RMDA's weekly volatility (5%) has been stable over the past year.
About the Company
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E., together with its subsidiaries, produces and sells a range of branded generic pharmaceuticals and nutraceuticals in Egypt. It manufactures, markets, sells, and stores pharmaceutical reagents for human and veterinary use; and diagnostic reagents for individuals, laboratories, and hospitals. The company offers a portfolio of products in various therapeutic areas, such as anti-infective, anti-diabetic, respiratory, ophthalmology, gastrointestinal tract, cardiovascular, central nervous system, vitamins, and analgesics.
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. Fundamentals Summary
|RMDA fundamental statistics|
Is RMDA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RMDA income statement (TTM)|
|Cost of Revenue||ج.م760.92m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.26|
|Net Profit Margin||17.10%|
How did RMDA perform over the long term?See historical performance and comparison